Home » Health » Doctors Seek Best Treatments for New Genetic Disease

Doctors Seek Best Treatments for New Genetic Disease

by Dr. Jennifer Chen

VEXAS Syndrome: A⁢ Newly Defined Inflammatory Condition Primarily Affecting Men

Published August 19, 2025

Understanding VEXAS ⁣Syndrome

Scientists are shedding light on VEXAS syndrome, a rare and ⁤frequently⁤ enough severe inflammatory autoimmune condition that emerged as a clearly defined entity ⁤only in recent years. First described in 2020, VEXAS-which stands for vacuoles, X-linked, auto-inflammatory, somatic-primarily affects men‍ over the age of 50 and is characterized by a wide range of symptoms⁢ stemming from the immune system attacking the body’s own⁢ cells.The condition can lead to significant inflammation and organ damage, and unfortunately, carries a high mortality rate.

The Role of Acquired Genetic Mutations

For a long time, genetic mutations were thought to be conditions people were born with. However, research is increasingly demonstrating that genes can change throughout life, sometimes leading to ⁤illness.These are known as acquired mutations, and can​ be influenced by ‌factors like exposure​ to radiation or certain chemicals. VEXAS syndrome is caused by these ⁢acquired mutations,specifically within the UBA1 gene,and is ⁣not inherited from parents.

“some of⁤ the‍ normal aging is that all our cells develop mutations. It is indeed⁣ only​ the normal wear of the cells in the body as we grow old,” explains Dr.David Beck, a geneticist involved in the initial discovery of VEXAS.

Why Men Are Disproportionately Affected

The UBA1 gene ‍provides ​instructions for creating an⁤ enzyme crucial for removing damaged proteins from cells. Mutations in this gene disrupt this process, triggering an inflammatory response. A key ⁢factor in VEXAS’s prevalence among men lies in their genetic makeup. Men have one X chromosome (and one Y chromosome), meaning they possess only one copy of the UBA1 gene. ⁤If that single copy ⁤is mutated, there’s no backup to compensate. ​

Women, with two ‍X chromosomes, have two ⁣copies of the UBA1 gene. If one copy is mutated, ⁣the other can frequently enough maintain normal function. For a woman to develop VEXAS,both copies of‌ the gene must be affected,a ‍far less common occurrence.

recognizing the Varied Symptoms of VEXAS

VEXAS syndrome ‌presents a complex clinical picture, making diagnosis challenging. Symptoms can vary considerably between individuals and may mimic other inflammatory conditions. Common symptoms include:

  • Fever
  • Fatigue
  • Skin rash
  • Pain and swelling, especially in the nose and ears
  • Blood clots and ​inflamed blood vessels
  • Pulmonary inflammation (difficulty breathing, cough)
  • Anemia ⁢(low red blood cell count)
  • Low platelet levels

In severe cases, VEXAS can lead to thrombocytopenia (low platelet count) and refractory​ anemia, indicating ⁤progressive bone marrow failure.

Diagnosis and Emerging Treatments

Diagnosis of ⁤VEXAS syndrome involves testing for ⁢mutations in the UBA1 gene. currently,​ there ‌is no cure for VEXAS, but treatments⁤ focus ‌on managing inflammation. Steroids and ⁤other immunosuppressants can definitely help reduce inflammation, though their effectiveness and long-term durability can be limited. Researchers are also exploring the use of medications typically used to treat blood cancers to address the impact of VEXAS on blood and bone marrow.

Recent research at IRCCS ​San Raffaele Hospital has revealed that VEXAS syndrome involves the buildup of toxic proteins within blood cells, triggering inflammation. This discovery, made using innovative genome editing technology in April, is informing new therapeutic strategies.

The complexity of VEXAS requires a multidisciplinary approach to care, involving specialists such as rheumatologists, hematologists, pulmonologists, and dermatologists.

Ongoing Research and Clinical Trials

The National Institutes of Health ​(NIH) is currently recruiting participants for a ⁣ clinical study to evaluate the potential of bone marrow⁤ transplantation as a treatment for VEXAS syndrome.Furthermore,​ the American College of Rheumatology (ACR) released an international consensus guide in August, providing clinicians with essential guidance for understanding and managing this complex condition.

As⁣ Dr. ⁤Beck notes,”We are still learning about this disease. It has ⁢been recognized only in the last few years.” Continued research and clinical trials are vital⁣ to improving the lives of those ​affected by VEXAS syndrome.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.